The latest updated of drug registration lists on 03 May 2025.

Close

No Brand Name Ingredients Dosage Form Primary Packaging Indications EDL License Owner Manufacturer Country Activity Reg No. Reg Date Expiry Date Action
341 CABOCARE 20 CABOZANTINIB (S)-MALATE EQ.TO CABOZANTINIB 20 MG CAPSULE BOTTLE FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN TREATMENT NAIVE ADULTS WITH INTERMEDIATE OR POOR RISK, IN ADULTS FOLLOWING PRIOR VASCULAR ENDOTHELIAL GROUTH FACTOR TARGETED THERAPY, AS MONOTHERAPYFOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN ADULTS WHO HAVE PREVIOUSLY BEEN TREATED WITH SORAFENIB No BOTEN ELEMENTO PHARMA FACTORY BOTEN ELEMENTO PHARMA FACTORY LAO PDR CERTIFICATE RELEASED 03 L 0852/21 2025-02-20 2030-02-19 View
342 AVACARE AVATROBOPAG 20 MG TABLET BOTTLE TREATMENT OF THROMBOCYTOPENIA IN PATIENT WITH CHRONIC LIVER DISEASE AND CHRONIC IMMUNE THROMBOCYTOPENIA No BOTEN ELEMENTO PHARMA FACTORY BOTEN ELEMENTO PHARMA FACTORY LAO PDR CERTIFICATE RELEASED 02 L 1304/25 2025-02-24 2030-02-23 View
343 CABOCARE 80 CABOZANTINIB (S)-MALATE EQ.TO CABOZANTINIB 80 MG CAPSULE BOTTLE FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN TREATMENT NAIVE ADULTS WITH INTERMEDIATE OR POOR RISK, IN ADULTS FOLLOWING PRIOR VASCULAR ENDOTHELIAL GROUTH FACTOR TARGETED THERAPY, AS MONOTHERAPYFOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN ADULTS WHO HAVE PREVIOUSLY BEEN TREATED WITH SORAFENIB No BOTEN ELEMENTO PHARMA FACTORY BOTEN ELEMENTO PHARMA FACTORY LAO PDR CERTIFICATE RELEASED 03 L 0853/21 2025-02-20 2030-02-19 View
344 CAPMACARE CAPMATINIB HYDROCHLORIDE 200 MG TABLET BOTTLE FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WHOSE TUMORS HAVE A MUTATION THAT LEADS TO MESENCHYMAL-EPITHELIAL TRANSITION EXON 14 SKIPPINGT No BOTEN ELEMENTO PHARMA FACTORY BOTEN ELEMENTO PHARMA FACTORY LAO PDR CERTIFICATE RELEASED 03 L 0856/21 2024-08-07 2027-08-06 View
345 CRIZOCARE CRIZOTONIB 250 MG CAPSULE BOTTLE FIRST LINE TREATMENT OF ADULTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON SMALL CELL LUNG CANCER, TREATMENT OF ADULTS WITH PREVIOUSLY TREATED ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON SMALL CELL LUNG CANCER, TREATMENT OF ADULT WITH ROS1-POSITIVE ADVANCED NON SMALL CELL LUNG CANCER No BOTEN ELEMENTO PHARMA FACTORY BOTEN ELEMENTO PHARMA FACTORY LAO PDR CERTIFICATE RELEASED 03 L 0847/21 2024-08-07 2027-08-06 View
346 DACOCARE DACOMITINIB MONOHYDRATE EQ.TO DACOMITINIB 45 MG TABLET BOTTLE FOR THE FIRST LINETREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATIONS No BOTEN ELEMENTO PHARMA FACTORY BOTEN ELEMENTO PHARMA FACTORY LAO PDR CERTIFICATE RELEASED 03 L 0846/21 2025-02-20 2030-02-19 View
347 ELTHROMBOFE ELTROMBOPAG 25 MG CAPSULE BOTTLE TREATMENT OF THROMBOCYTOPENIA IN PATIENT WITH CHRONIC ITP No BOTEN ELEMENTO PHARMA FACTORY BOTEN ELEMENTO PHARMA FACTORY LAO PDR CERTIFICATE RELEASED 06 L 1119/24 2024-08-07 2027-08-06 View
348 ERDACARE ERDAFITINIB 3 MG CAPSULE BOTTLE TREARMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR 3 OR FGFR2 GENETIC ALTERATION AND PROGRESSD DURING OR FOLLOWING AT LEAST ONE LINE OF PRIOR PLATINUM-CONTAINING CHEMOTHERAPY INCLUDING WITHIN 12 MONTHS OF NEOADJUVANT OR ADJUVANT PLATINUM-CONTAINING CHEMOTHERAPY No BOTEN ELEMENTO PHARMA FACTORY BOTEN ELEMENTO PHARMA FACTORY LAO PDR CERTIFICATE RELEASED 03 L 0904/22 2022-03-30 2025-03-29 View
349 LENVACARE 10 LENVATINIB 10 MG CAPSULE BOTTLE AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROIDCARCINIMA, REFRACTORY TO RADIOACTIVE IODINE. AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA WHO HAVE RECEIVED NO PRIOR SYSTEMIC THERAPY No BOTEN ELEMENTO PHARMA FACTORY BOTEN ELEMENTO PHARMA FACTORY LAO PDR CERTIFICATE RELEASED 03 L 0851/21 2025-02-20 2030-02-19 View
350 LENVACARE 4 LENVATINIB 4 MG CAPSULE BOTTLE AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROIDCARCINIMA, REFRACTORY TO RADIOACTIVE IODINE. AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA WHO HAVE RECEIVED NO PRIOR SYSTEMIC THERAPY No BOTEN ELEMENTO PHARMA FACTORY BOTEN ELEMENTO PHARMA FACTORY LAO PDR CERTIFICATE RELEASED 03 L 0850/21 2025-02-20 2030-02-19 View
 
© 2014 ສະຫງວນລິຂະສິດໂດຍ ກົມອາຫານ ແລະ ຢາ, ກະຊວງສາທາລະນະສຸກ, ສປປລາວ.
ຕິດຕໍ່ ກອຢ      ອີເມວ      ເຂົ້າລະບົບ